Biolife Solutions Inc 8-K Filing
Ticker: BLFS · Form: 8-K · Filed: Nov 17, 2025 · CIK: 834365
| Field | Detail |
|---|---|
| Company | Biolife Solutions Inc (BLFS) |
| Form Type | 8-K |
| Filed Date | Nov 17, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Biolife Solutions Inc (ticker: BLFS) to the SEC on Nov 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share BLFS The Nasdaq Stock Market).
How long is this filing?
Biolife Solutions Inc's 8-K filing is 2 pages with approximately 533 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-11-17 07:00:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BLFS The Nasdaq Stock Market
Filing Documents
- blfs-20251117.htm (8-K) — 25KB
- blfsinvestorpresentation.htm (EX-99.1) — 41KB
- blfsinvestorpresentation001.jpg (GRAPHIC) — 135KB
- blfsinvestorpresentation002.jpg (GRAPHIC) — 205KB
- blfsinvestorpresentation003.jpg (GRAPHIC) — 69KB
- blfsinvestorpresentation004.jpg (GRAPHIC) — 121KB
- blfsinvestorpresentation005.jpg (GRAPHIC) — 118KB
- blfsinvestorpresentation006.jpg (GRAPHIC) — 117KB
- blfsinvestorpresentation007.jpg (GRAPHIC) — 145KB
- blfsinvestorpresentation008.jpg (GRAPHIC) — 148KB
- blfsinvestorpresentation009.jpg (GRAPHIC) — 146KB
- blfsinvestorpresentation010.jpg (GRAPHIC) — 128KB
- blfsinvestorpresentation011.jpg (GRAPHIC) — 149KB
- blfsinvestorpresentation012.jpg (GRAPHIC) — 95KB
- blfsinvestorpresentation013.jpg (GRAPHIC) — 136KB
- blfsinvestorpresentation014.jpg (GRAPHIC) — 96KB
- blfsinvestorpresentation015.jpg (GRAPHIC) — 93KB
- blfsinvestorpresentation016.jpg (GRAPHIC) — 112KB
- blfsinvestorpresentation017.jpg (GRAPHIC) — 115KB
- blfsinvestorpresentation018.jpg (GRAPHIC) — 84KB
- blfsinvestorpresentation019.jpg (GRAPHIC) — 106KB
- blfsinvestorpresentation020.jpg (GRAPHIC) — 103KB
- blfsinvestorpresentation021.jpg (GRAPHIC) — 132KB
- blfsinvestorpresentation022.jpg (GRAPHIC) — 83KB
- blfsinvestorpresentation023.jpg (GRAPHIC) — 46KB
- blfsinvestorpresentation024.jpg (GRAPHIC) — 84KB
- blfsinvestorpresentation025.jpg (GRAPHIC) — 79KB
- blfsinvestorpresentation026.jpg (GRAPHIC) — 104KB
- blfsinvestorpresentation027.jpg (GRAPHIC) — 99KB
- blfsinvestorpresentation028.jpg (GRAPHIC) — 98KB
- 0001628280-25-052479.txt ( ) — 4533KB
- blfs-20251117.xsd (EX-101.SCH) — 2KB
- blfs-20251117_lab.xml (EX-101.LAB) — 21KB
- blfs-20251117_pre.xml (EX-101.PRE) — 12KB
- blfs-20251117_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 17, 2025, BioLife Solutions, Inc. (the "Company") issued an investor presentation. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The investor presentation is also available on the Company's website located at https://investors.biolifesolutions.com/image/BLFS+Investor+Presentation+2025.pdf. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and will not be deemed to be "filed" for any purpose, including for the purposes of Section 18 the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor will such information or exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated November 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioLife Solutions, Inc. Date: November 17, 2025 By: /s/ Troy Wichterman Name: Troy Wichterman Title: Chief Financial Officer